◾ Type 2 diabetes mellitus (T2DM) generally occurs in people older than 40 years; the incidence increases with age, with more than 10% of people over 65 years having T2DM. In recent years, T2DM more often arises at a younger age due to an increasingly obese society, poor dietary habits, and sedentary lifestyles 1-3 ◾ T2DM is a major public health problem and affects 10 million people in Europe (4% of the total population). Based on World Health Organization (WHO) estimates, the number of people with diabetes could be over 350 million throughout the world by 2030 4 ◾ Canagliflozin (CANA) is a novel, oral antihyperglycaemic agent (AHA) with sodium glucose co-transporter 2 (SGLT2) inhibition activity developed for the treatment of adults with T2DM 5-16 ; CANA (100 or 300 mg once daily) was approved for use in the European Union in November 2013
◾ Patient baseline characteristics were taken from the relevant CANA trial in that setting. Treatment effects also came from these trials, with the exception of the comparison to SITA in triple therapy and with DAPA as an add-on to insulin, where treatment effects were taken from the results of a network meta-analysis (NMA; Pacou et al 22 and data on file) since direct comparisons were not available ( Table 1) -Clinical data inputs were for CANA 100 mg and DAPA 10 mg, as these dosages are likely to be most commonly used in the Czech Republic ◾ HbA1c and SBP progressed for each patient according to UKPDS 68. 24 Lipid values progressed according to the equations from the Framingham Heart Study. 25 BMI progression was conservatively assumed to be flat. The risk of cardiovascular complications was obtained using the UKPDS Outcomes Model 24 ◾ In the model, patients discontinued treatment when the related trial baseline HbA1c was reached, at which point they switched to insulin at a dose of 40 IU/day after add-on to MET or add-on to MET plus SU. The trial baseline HbA1c was used as the switching threshold, in the absence of local guidelines, because this was the level of HbA1c at which patients included in the trial were intensifying or switching their treatment regimen; it was therefore a reasonable assumption that patients would switch or intensify once they reached the trial baseline HbA1c. For the add-on to insulin comparison, patients started on 83 IU as their daily insulin dose. After discontinuation of CANA 100 mg or DAPA 10 mg, insulin was intensified by 25% to give a daily dose of 104 IU ◾ AEs included in the model were urinary tract infections and genital mycotic infections. AE rates were taken from trial data, except for SITA in triple therapy (assumed to have the same rate of AE events as the placebo arm in DIA3002) and for DAPA (assumed to have the same rate of AEs as CANA) -In the CANA studies, rates of urinary tract infections were generally similar across groups; there was a higher incidence of genital mycotic infections with CANA versus comparator treatments ◾ Hypoglycaemia events were included as severe or non-severe in the model ◾ Interim life tables for the Czech Republic were obtained from the Czech Statistical Office (December 2013). These life tables include all causes of mortality, so they had to be adjusted to remove mortality caused by diseases explicitly modelled in the CDM 26
Economic Inputs
◾ Cardiovascular complication costs are shown in Table 2 . Renal complication costs were obtained from Klimeš et al. 27 Other complication costs were obtained from Czech-specific sources where available. The public prices of each pack were specified as those relevant to the Czech government reimbursement authority ◾ Historical data indicate that the willingness-to-pay threshold is around 1,100,000 CZK per quality-adjusted life year (QALY)
◾ For T2DM and its complications, health state utilities for the model were derived wherever possible from the UKPDS, 28 which covers the majority of microvascular and macrovascular health states, and were supplemented with data from other sources as necessary ◾ Cost and health benefits were discounted at 3%. The time horizon used for the economic evaluation was 40 years, to reflect the chronic nature of the disease
RESULTS
◾ The cost-effectiveness analyses suggested that in dual therapy when compared to SITA and GLIM, CANA 100 mg was cost-effective, with an incremental cost-effectiveness ratio (ICER) of 242,783 CZK and 626,939 CZK per QALY gained, respectively. In triple therapy when compared to SITA, analyses suggested that CANA 100 mg is cost-effective, with an ICER of 335,759 CZK per QALY gained. The results are summarised in Table 3 . As an add-on to insulin, analyses suggested that CANA is cost-effective compared to DAPA, with an ICER of 375 CZK per QALY gained, albeit the differences in costs and QALYs were small ◾ The cost-effectiveness planes are shown in Figure 2 . The cost-effectiveness acceptability curves are shown in Figure 3 . Using the willingness-to-pay threshold of 1,100,000 CZK, the probability of CANA being cost-effective is more than 50% in each comparison ◾ Favourable clinical outcomes for CANA translate into long-term health benefit gains in all comparisons, with the largest QALY gain versus GLIM. At the same time, total treatment costs in CANA treatment arms were higher through all comparisons, with a lowest cost difference versus DAPA. However, all ICER results were below the acceptability threshold assumed for the Czech Republic ◾ A conservative approach has been applied in all simulations in relation to the benefit associated with weight loss, and in terms that the benefit from each treatment is reversed at the point of discontinuation (ie, immediate weight rebound is assumed to happen after discontinuation) BMI, body mass index; SBP, systolic blood pressure; SE, standard error. *Mean change ± SE from baseline. †Event rate per 100 patient-years. ‡Taken from the placebo arm of the DIA3002 trial. § Assumed to be the same as CANA 100 mg. 
